Centrum Capital Limited (NSE:CENTRUM)

CTI BioPharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-1,875	-993.49	-1,498	-1,767	-468.72
Depreciation & Amortization, Total	1,033	668.26	348.3	193.63	175.01
Gain (Loss) On Sale of Investments	6,842	1,099	356.45	1,143	-51.66
Stock-Based Compensation	25.06	45.26	94.02	-46.7	39.8
Change in Accounts Receivable	-288.15	-122.7	-16.8	-66.31	275.94
Change in Accounts Payable	-207.72	230.27	77.04	317.71	-33.43
Change in Other Net Operating Assets	18,375	-1,488	-41,487	32,390	-1,212
Other Operating Activities	2,584	2,145	1,371	1,201	842.33
Operating Cash Flow	25,324	1,199	-40,906	33,308	-403.68
Capital Expenditures	-4,142	-1,022	-248.07	-480.45	-53.94
Cash Acquisitions	-	-87.5	-1,263	-	-
Investment in Securities	-13,351	-14,491	3,250	-2,929	-539.86
Other Investing Activities	412.5	95.78	117.51	502.88	91.43
Investing Cash Flow	-17,076	-15,502	1,414	-2,859	-568.83
Long-Term Debt Issued	859.43	16,006	4,568	3,781	6,840
Total Debt Issued	859.43	16,006	4,568	3,781	6,840
Long-Term Debt Repaid	-3,896	-152.01	-3,022	-2,583	-4,567
Total Debt Repaid	-3,896	-152.01	-3,022	-2,583	-4,567
Net Debt Issued (Repaid)	-3,037	15,854	1,546	1,199	2,273
Issuance of Common Stock	86.55	-	8.75	7,457	6.25
Other Financing Activities	-2,917	-820.32	-574.98	-1,281	-904.15
Financing Cash Flow	-5,868	15,034	979.34	7,374	1,375
Net Cash Flow	2,380	708.81	-38,367	42,263	402.85
Free Cash Flow	21,183	176.71	-41,154	32,827	-457.62
Free Cash Flow Growth	11887.34%	-	-	-	-
Free Cash Flow Margin	223.49%	1.58%	-613.78%	1125.76%	-18.45%
Free Cash Flow Per Share	50.92	0.42	-98.92	78.91	-1.10
Cash Interest Paid	2,917	800.32	574.98	1,281	904.15
Cash Income Tax Paid	321.33	101.4	22.7	160.88	-27.79

Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Capital Markets template. Financial Sources.